Status:
COMPLETED
Comparing Buzzy Device With Emla Cream in Needle Related Pain
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Procedural Pain
Eligibility:
All Genders
2-14 years
Brief Summary
This randomized controlled study will enroll the eligible patients to either the Buzzy device arm or to the EMLA cream arm as a standard therapy. This will be done with concealment; however, blinding ...
Detailed Description
Currently there is strong evidence that children regardless the age feel pain. Research were done and still going on to handle the barriers for pain management in children. Several pain management too...
Eligibility Criteria
Inclusion
- All children attending Al Saad PEC with age of 2 up to 14 years of age. Decision made by the treating physician in the PEC for IV catheter placement or blood extraction
Exclusion
- Older than 14 years of age or younger than 2 years of age.
- Children who require immediate emergency intervention, category 1 and 2 in the Canadian Triage and Acuity Scale.
- Diseases rendering patient to be sensitive to cold such as Sickle Cell disease or patients with Reynaud's phenomena.
- Skin damage of any degree in the limb where the needle will be inserted.
- Patients with abnormal sensation in the targeted limb for needle insertion.
- Any degree of neurological, psychological, or psychiatric disability.
- Received simple analgesics, paracetamol and nonsteroidal anti-inflammatory drugs within 6 hours prior the procedure.
- Received procedural sedation/analgesia, any sedative, opioid analgesic, or dissociative drug such as ketamine within 4 hours from the needle prick. Known hyper sensitivity to local anesthetics or any conditions that need precautions to EMLA cream such as G-6PD deficiency, methemoglobinemia, atopic dermatitis or other skin lesion in the needle prick site, patient using antiarrhythmic drug such as amiodarone.
- Refusal of signing the consent.Known hyper sensitivity to local anesthetics or any conditions that need precautions
Key Trial Info
Start Date :
February 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05354739
Start Date
February 2 2021
End Date
September 29 2021
Last Update
April 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar, 3050